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Abstract: 27 
Non-coding RNAs are important regulators of gene expression and transcription. It is well 28 
established that impaired non-coding RNA expression especially the one of long non-coding 29 
RNAs and microRNAs is involved in a number of pathological conditions including cancer. 30 
Non-coding RNAs are responsible for the development of resistance to anticancer treatments 31 
as they regulate drug resistance-related genes, affect intracellular drug concentrations, induce 32 
alternative signalling pathways, alter drug efficiency via blocking cell cycle regulation and 33 
DNA damage response. Furthermore, they can prevent therapeutic-induced cell death and 34 
promote epithelial-mesenchymal transition and elicit non-cell autonomous mechanisms of 35 
resistance.  36 
In this review we summarise the role of non-coding RNAs for different mechanisms resulting 37 
in drug resistance (e.g. drug transport, drug metabolism, cell cycle regulation, regulation of 38 
apoptotic pathways, cancer stem cells and epithelial-mesenchymal transition) in the context 39 
of gastrointestinal cancers. 40 
 41 
Introduction: 42 
Gastrointestinal (GI) cancer encompasses a heterogeneous group of tumours that affect the 43 
digestive tract system (Pourhoseingholi et al., 2015). These include cancers of the 44 
oesophagus, stomach, gallbladder, liver and biliary tract, pancreas, small intestine, colon, 45 
rectum and anus. GI cancer is the most common form of cancer responsible for nearly 25% of 46 
all new cancer diagnosis and responsible for most of cancer related death (around 30% of all 47 
cancer related death) worldwide (Siegel et al., 2015;Torre et al., 2015).   48 
Chemotherapy is, alongside with surgery and radiation therapy, one of the main treatments 49 
for cancer (Hung et al., 2006;Chan et al., 2016;Ismael et al., 2016;Jakhetiya et al., 50 
2016;Murphy, 2016;Olcina and Giaccia, 2016;Rautio et al., 2016;Ristamaki and Algars, 51 
2016;Rutkowski and Hompes, 2016). Many chemotherapeutic agents have successfully 52 
prolonged overall and progression-free survival of GI cancer patients (Slamon et al., 53 
2001;Motzer et al., 2007;Blanke et al., 2008;Maemondo et al., 2010;Chapman et al., 2011). 54 
In addition, a better understanding of the biology and mechanism underpinning GI cancer 55 
initiation and progression is leading to more personalised treatments. Indeed, identification of 56 
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well-defined molecular subtypes and/or molecular profiling of somatic mutations offer the 57 
opportunity to further optimize the efficacy of treatments through tailored approaches (Kwak 58 
et al., 2010;Douillard et al., 2013;Korpanty et al., 2014;Siroy et al., 2015).  59 
Despite major improvements in the management of GI cancer patients, resistance to  60 
therapies arises almost inevitably at some point during the treatment and chemo-resistance is 61 
one of the main challenges in cancer therapy (Housman et al., 2014). Drug resistance can be 62 
caused by gene mutations, abnormal DNA repair, alteration in cell cycle regulation, cell death 63 
inhibition (mostly caused by deregulated apoptotic signalling pathways), reduced drug 64 
efficacy as well as enhanced drug clearance (Zahreddine and Borden, 2013;Housman et al., 65 
2014). Furthermore, the epithelial-mesenchymal transition (EMT) process and the presence 66 
of tumour stem cells have been identified as causes of drug resistance (Shang et al., 2013;Xia 67 
and Hui, 2014;Mitra et al., 2015;Prieto-Vila et al., 2017). The complex molecular 68 
mechanisms of chemo-resistance have not been fully elucidated yet and a better 69 
understanding of drivers of primary and secondary resistance to chemotherapy will likely 70 
result into improved patients’ survival. Increasing evidence points towards the role of non-71 
coding RNAs as a central hub for treatment resistance. Therefore, this review outlines the 72 
role of non-coding RNAs for the different drug resistance mechanisms involved in GI cancer 73 
therapy failure. Table 1 summarised the non-coding RNAs discussed in this review and in 74 
figure 1-6 the role for each of these non-coding RNAs in the context of the different GI 75 
tumours is illustrated. 76 
 77 
Non-coding RNAs: 78 
In human tissues the amount of non-coding RNAs is more than three times higher compared 79 
to the amount of protein-coding RNAs (Geisler and Coller, 2013). Non-coding RNAs are a 80 
large family that includes more than 16 categories of long and short RNA molecules (Table 81 
2); among them transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), small nucleolar RNAs 82 
(snoRNAs), endogenous small interfering RNAs (endo-siRNAs), sno-derived RNAs 83 
(sdRNAs), transcription initiation RNAs (tiRNAs), miRNA-offset-RNAs (moRNAs), circular 84 
RNAs (circRNAs), vault RNAs (vRNAs), microRNAs, small interfering RNAs (siRNAs), 85 
small nuclear RNAs (snRNAs), extracellular RNAs (exRNAs), piwi-interacting RNAs 86 
(piRNAs), small Cajal body RNAs (scaRNAs), long intergenic non-coding RNAs 87 
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(lincRNAs) and long non-coding RNAs (lncRNAs), all of which are not coding for known 88 
proteins (Taal et al., 1993;Eddy, 2001;He and Hannon, 2004;Guttman et al., 89 
2009;Langenberger et al., 2009;Taft et al., 2009a;Taft et al., 2009b;Wilusz et al., 90 
2009;Choudhuri, 2010;Ling et al., 2013;Claycomb, 2014;Guo et al., 2014;An et al., 91 
2016;Azlan et al., 2016;Beermann et al., 2016;de Almeida et al., 2016;Evans et al., 92 
2016;Geiger and Dalgaard, 2016;Granados-Riveron and Aquino-Jarquin, 2016;Khurana et 93 
al., 2016;Qi et al., 2016;Quinn and Chang, 2016).  94 
Long non-coding RNAs (lncRNAs) and microRNAs are the most studied non-coding RNAs 95 
playing a role in anticancer drug resistance and will be covered in this review.  96 
LncRNAs are composed of more than 200 nucleotides. They are important regulators during 97 
development and pathological processes (Guttman et al., 2011;Sauvageau et al., 98 
2013;Herriges et al., 2014;Li et al., 2014a;Ounzain et al., 2014). LncRNAs are pivotal in 99 
regulating gene expression by binding to chromatin regulatory proteins and they are able to 100 
alter chromatin modification as well as transcriptional or post-transcriptional gene regulation 101 
by interacting with other RNAs and proteins (Moran et al., 2012;Kornienko et al., 2013;Han 102 
and Chang, 2015). Recently, a crosstalk and strong linkage between lncRNA and microRNAs 103 
has been identified (Yoon et al., 2014). It has been shown that lncRNA stability can be 104 
reduced by interaction with specific microRNAs and, vice versa, lncRNAs act as microRNA 105 
decoys sequestering microRNAs from the intra-cellular cytosol and leading to re-expression 106 
of microRNA target genes (Yoon et al., 2014). Furthermore, lncRNAs can promote gene 107 
expression by competing with microRNAs for specific binding sites in the non-coding 108 
regions of mRNAs and prevent the transcriptional repression caused by microRNAs (Yoon et 109 
al., 2014). Interestingly some lncRNAs can be processed into microRNAs (Yoon et al., 2014) 110 
suggesting a plastic interaction among different classes of non-coding RNAs.  111 
MicroRNAs are short RNA transcripts of 18–24 nucleotides. They are responsible for fine 112 
tuning cell homeostasis by controlling gene expression at post-transcriptional level, (Fabbri et 113 
al., 2009;Valeri et al., 2009;Winter et al., 2009). Due to the fact that each microRNAs can 114 
have several target mRNAs the interaction of one microRNA with various target mRNAs 115 
results in direct deregulation of different target proteins acting simultaneously in regulation of 116 
diverse cellular pathways (Macfarlane and Murphy, 2010;Pasquinelli, 2012). Therefore, 117 
variation in microRNA expression can result in reduced mRNA levels ultimately resulting in 118 
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changes in protein levels within the cell (von Schack et al., 2011;Pasquinelli, 2012). 119 
MicroRNAs expression patterns are tissue-specific (Lagos-Quintana et al., 2002) and often 120 
define the physiological status of the cell (Lim et al., 2005). Strong clinical and pre-clincial 121 
evidence suggests that microRNA aberrant expression plays a role in several diseases 122 
including cancer, infectious, neurodegenerative and immune-related diseases. (Murakami et 123 
al., 2006;Mitchell et al., 2008;O'Connell et al., 2010;Esteller, 2011;Ha, 2011b;a;c;Grasedieck 124 
et al., 2012;Iorio and Croce, 2012;Acunzo et al., 2015;Balatti et al., 2015;Gardiner et al., 125 
2015). Analysis of microRNA expression patterns represents a promising tool for cancer 126 
diagnosis, prognosis and treatment prediction.  MicroRNAs have been extensively studied in 127 
monitoring treatment resistance in consideration of their high stability in tissues and body 128 
fluids. In blood, microRNAs are included in RNA-binding multiprotein complexes and/or 129 
exosomes and their short length makes microRNAs less prone to degradation and improves 130 
their stability under different sample storage conditions in blood (Mitchell et al., 131 
2008;Macfarlane and Murphy, 2010;Grasedieck et al., 2012;Gardiner et al., 2015) . 132 
 133 
General principles of drug resistance: 134 
Drug resistance is classified into intrinsic and acquired. Primary drug resistance is pre-135 
existing and renders cancer cells immune against the therapy from the very beginning. In 136 
contrast, acquired (secondary) drug resistance develops during therapy due to adaptive 137 
processes of the tumour (Gottesman et al., 2002;Longley and Johnston, 2005;Rodrigues et al., 138 
2012a;Holohan et al., 2013;Housman et al., 2014). Different mechanisms are involved in 139 
primary and acquired drug resistance and relate to non-coding RNAs dysregulation.  140 
 141 
 142 
Deregulation of proteins involved in drug metabolism 143 
One reason for drug resistance can be found on the level of drug transport. Reduced influx or 144 
increased efflux of chemotherapeutics result in lower intracellular drug concentrations and 145 
promotes therapy failure (Gottesman et al., 2002). Altered drug metabolism is another 146 
possible cause for drug resistance. Drug metabolism is a complex pathway composed of 147 
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multiple proteins for detoxification of foreign compounds (e.g. chemotherapeutics) normally 148 
neither produced nor present in a cell (Michael and Doherty, 2005). This pathway can be 149 
subdivided into modification (phase I reaction), conjugation (phase II reaction) and excretion 150 
(phase III reaction) (Park, 2001). Several drug-metabolizing enzymes, especially members of 151 
the cytochrome P450 family, together with drug transporters increase the polarity of the drugs 152 
during phase I (Shimada et al., 1989;Guengerich and Shimada, 1991) . In the following phase 153 
II the polarity of the drugs is further increased by conjugation reactions (Shea et al., 154 
1988b;McLellan and Wolf, 1999b). Finally, in phase III the resulting drug metabolites are 155 
exported by transmembrane transporter like ATP-binding cassette (ABC) proteins and solute 156 
carrier (SLC) transport proteins (Dean et al., 2001;Kathawala et al., 2015;Lin et al., 157 
2015;Colas et al., 2016).  158 
 159 
The vaults are known to contribute to drug resistance by transporting drugs away from their 160 
intracellular targets and vaults are involved in drug sequestration (Mossink et al., 2003). The 161 
vRNAs hvg-1 and hvg-2 that are present in the vaults (Table 2) interact with drugs via 162 
specific binding sites (Gopinath et al., 2010). In agreement with their role in regard to drug 163 
resistance the number of vaults are increased in cancer patients who developed resistance 164 
under chemotherapy (Mossink et al., 2003).  In addition, the vRNAs are producing several 165 
small RNAs among them is svRNAb which down-regulates the key enzyme in drug 166 
metabolism CYP3A4 and accounts so for multidrug resistance in GI cancers (Persson et al., 167 
2009). 168 
Furthermore, lncRNA H19 was identified as another non-coding RNA involved in drug 169 
resistance. The oncogenic potential of lncRNA H19 was demonstrated in different tumour 170 
types (e.g. liver and oesophageal cancer) and over-expression of lncRNA H19 was observed 171 
in parallel with up-regulation of the membrane glycoprotein p95 in multidrug-resistant 172 
tumours (Tsang and Kwok, 2007;Matouk et al., 2013). In liver tumour cells resistant to 173 
doxorubicin, etoposide, paclitaxel and vincristine lncRNA H19 expression was increased 174 
(Tsang and Kwok, 2007). LncRNA H19 participate in the regulation of MDR1 gene (also 175 
known as ABCB1 gene) expression and modulate the drug transport out of the cell (Tsang and 176 
Kwok, 2007). In-vitro models of hepatocellular carcinoma suggest that lncRNA H19 can alter 177 
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MDR1 promoter methylation and, in doing so, increases the transcription of P-glycoprotein 178 
(Tsang and Kwok, 2007).  179 
Similarly, in gastric cancer, lncRNA MRUL (MDR-related and up-regulated lncRNA) acts as 180 
an enhancer for transcription of P-glycoprotein (MDR1) (Wang et al., 2014) increasing the 181 
number of transmembrane transporters on the tumour cell membrane and fosters the drug 182 
export (Wang et al., 2014). As we described above, different non-coding RNAs can merge 183 
onto the same pathway: this is the case of lncRNA AK022798 whose expression is induced 184 
by  NOTCH-1 over-expression during gastric cancer progression (Hang et al., 2015). 185 
LncRNA AK022798 in turn up-regulates the expression of P-glycoprotein and is responsible 186 
for increased cisplatin resistance in gastric cancer patients (Hang et al., 2015). Similarly, in 187 
cisplatin and 5-fluorouracil resistant gastric cancer patients the expression of lncRNA PVT-1 188 
(plasmacytoma variant translocation 1) and lncRNA ANRIL (antisense to CDKN2B locus) 189 
are also increased and these non-coding RNAs promote MDR1 up-regulation and drug 190 
resistance (Zhang et al., 2015b;Lan et al., 2016).  191 
Non-coding RNA dysregulation is tissue specific, indeed Wnt-β-catenin pathway activation 192 
triggers the expression of a different lncRNA, CCAL (colorectal cancer-associated lncRNA. 193 
The effect on phenotype is the same as in other cancers given CCAL in turn up-regulates P-194 
glycoprotein expression and causing chemotherapy resistance (Ma et al., 2016b).  195 
Additional to the regulation via lncRNAs ABC transporter expression levels are also 196 
controlled by miRNAs (Haenisch et al., 2014;Ikemura et al., 2014).  197 
In colon cancer, P-glycoprotein expression was found to be directly deregulated at post-198 
transcriptional level by binding of miR-145 to the 3`-UTR of the MDR1 gene transcript 199 
(Ikemura et al., 2013). Down-regulation of miR-145 results in increased ABCB1 protein level 200 
(Ikemura et al., 2013). Analogously miR-297 binds to the 3´-UTR of ABCC2 mRNA and 201 
supresses the expression of ABCC2 transporter (Xu et al., 2012). In chemo-resistant 202 
colorectal carcinoma, miR-297 is often down-regulated and consequently ABCC2 is 203 
expressed on a higher level compared to the surrounding colon tissue (Xu et al., 2012). 204 
Interestingly, in-vitro and in-vivo models suggest that resistance to vincristine and oxaliplatin 205 
could be overcome by restoring miR-297 expression in therapy resistant cells (Xu et al., 206 
2012). Virtually expression of all the transporters can be affected by microRNA 207 
dysregulation; ABCB5 transporter is highly expressed in colon cancer cell lines with down-208 
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regulated miR-522 expression and renders these cells resistant to doxorubicin treatment 209 
(Yang et al., 2015). MiR-522 binds to the ABCB5 mRNA 3´-UTR and over-expression of 210 
miR-522 reverse chemo-resistance to doxorubicin  (Yang et al., 2015). Similarly, 5-211 
fluorouracil resistance in microsatellite instable colon cancer (caused by deregulated miR-21 212 
or miR-155 (Valeri et al., 2010a;Valeri et al., 2010b) as mentioned in detail later) can be 213 
enhanced by down-regulation of miR-23a resulting in higher expression of the direct target 214 
ABCF1 (Li et al., 2015d). 215 
Similar examples exist across the board: in gastric cancer for example, down-regulation of 216 
miR-508-5p was identified as a reason for multidrug resistance (Shang et al., 2014). MiR-217 
508-5p represses the expression of P-glycoprotein and the transcription factor zinc ribbon 218 
domain-containing 1 (ZNRD1) that is an important factor for MDR1 gene translation (Shang 219 
et al., 2014). Loss of miR-508-5p decreased drug sensitivity in gastric cancer in-vitro and in-220 
vivo, whereas ectopic expression of miR-508-5p overcomes drug resistance (Shang et al., 221 
2014). 222 
 223 
In pancreatic cancer cell lines, expression of the transporter ABCC1 is controlled by miR-224 
1291 binding to the 3´-UTR (Pan et al., 2013). MiR-1291 is often down-regulated in 225 
pancreatic cancer resulting in an increased expression of ABCC1 that finally leads to higher 226 
efflux rate of toxic substances (Munoz et al., 2007;Tu et al., 2016). This is the reason for 227 
resistance to many chemotherapeutics, such as anthracyclines (e.g., doxorubicin), platinum 228 
derivates and the folate antagonist methotrexate (Munoz et al., 2007;Tu et al., 2016). Another 229 
transporter, called ATP7A (ATPase Cu
2+
 transporting alpha polypeptide), is up-regulated in 230 
in-vitro models of resistant pancreatic tumours due to decreased expression of miR-374b 231 
(Schreiber et al., 2016) and increased ATP7A protein expression is at least partially 232 
responsible for cisplatin resistance in pancreatic cancer model systems (Schreiber et al., 233 
2016).  234 
Down-regulation of miR-122 in liver tumours results in high expression of ABC transporter 235 
proteins and causes increased drug export of doxorubicin in liver cancer patients (Xu et al., 236 
2011). Similarly, ABCB1 transporter expression is up-regulated in hepatocellular cancer cells 237 
when the post-transcriptional regulator miR-223 is down-regulated and the result is again 238 
resistance to doxorubicin treatment (Yang et al., 2013b). 239 
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Down-regulation of microRNAs let-7g and let-7i results in increased expression of ABCC10 240 
that in turn is responsible for resistance to cisplatin therapy in oesophageal cancer patients 241 
(Wu et al., 2016a). 242 
An important barrier for oral anticancer drugs is represented by intestinal epithelial cells of 243 
the GI tract (Ikemura et al., 2014;Peterson and Artis, 2014). The absorption of most nutrient 244 
components as well as drugs is related to a variety of influx transporters such as members of 245 
the SLC transporter family (Ikemura et al., 2014). The expression pattern of the SLC 246 
transporter varied according to the differentiation status of intestinal epithelial cells which is 247 
controlled by microRNAs (McKenna et al., 2010). Therefore, changes in the expression level 248 
of microRNAs have most probably an important influence on the drug up-take rate 249 
(McKenna et al., 2010). Up to now the role of microRNAs for the expression level of SLC 250 
transporter have been studied only in cell culture models for colon carcinoma, liver, 251 
pancreatic and gastric tumours (Dalmasso et al., 2011;Pullen et al., 2011). In colon cancer 252 
cells expression of miR-92b reduce the amount of SLC15A and SLC15A1 transporter 253 
resulting in decreased drug absorption (Dalmasso et al., 2011). In the context of liver and 254 
pancreatic tumours miR-29a, miR-29b and miR-124 target SLC16A1 and reduce the 255 
expression of this transporter (Pullen et al., 2011). Recently it was shown that miR-939 256 
targets direct SLC34A2 in gastric cancer (Zhang et al., 2017). In 5-fluorouracil resistant 257 
gastric cancer miR-939 is down-regulated and results in increased expression level of 258 
SLC34A2. The transport protein SLC34A2 acts as mediator of miR-939 and activates the 259 
Ras/MEK/ERK pathway which is known to be deregulated often in cancer and to cause 260 
resistance to chemotherapy (Zhang et al., 2017). In in-vitro models of gastric cancer over-261 
expression of miR-939 strongly decreased MEK1/2 phosphorylation as well as Raf-1 level, 262 
whereas SLC34A2 restoration rescued these effects (Zhang et al., 2017).  263 
Also for some drug-metabolizing enzymes post-transcriptional regulations by miRNAs have 264 
been proven (Tsuchiya et al., 2006;Koturbash et al., 2012;Ikemura et al., 2014). Due to their 265 
pivotal role in maintaining chemical and functional homeostasis of cells, cytochrome P450 266 
enzymes are strictly controlled. Under physiological conditions, cytochrome P450 enzymes 267 
are involved in the regulation of endogenous molecules like bile acids and steroids and under 268 
pathological conditions in the case of chemotherapy these enzymes are important in regard to 269 
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drug metabolism. De-regulated expression of cytochrome P450 enzymes is linked to drug 270 
resistance and therapy failure (Rendic and Guengerich, 2015).  271 
For example, miR-378 targets mRNA coding for CYP2E1 and reduces the expression level of 272 
CYP2E1 protein in cell culture models of liver tumours (Mohri et al., 2010;Zhou et al., 273 
2016). In liver cancer patients CYP2E1 expression is increased while miR-378 is down-274 
regulated (Mohri et al., 2010;Zhou et al., 2016). Also, a direct regulation of CYP1B1 by miR-275 
27b was demonstrated in hepatocellular cancer cell lines (An et al., 2017). Decreased 276 
expression of miR-27b results in high expression level of CYP1B1 and renders by this liver 277 
tumour resistant to docetaxel treatment (An et al., 2017).  278 
In pancreatic cancer cells over-expression of miR-27b leads to down-regulation of CYP3A4 279 
protein and results in drug resistance to cyclophosphamide because CYP3A4 is necessary for 280 
drug activation (Pan et al., 2009). MicroRNA-based regulation of enzymes involved in phase 281 
II reactions are less analysed but nevertheless, in the context of oesophageal cancer, 282 
regulation of glutathione S-transferase P1 (GSTP1) was found to be regulated by miR-133a 283 
(Kano et al., 2010). Reduced expression of the tumour suppressor miR-133a resulted in 284 
increased level of GSTP1 protein (Kano et al., 2010). In phase II detoxification reactions -285 
including inactivation of platinum derivates and alkylating reagents -GSTP1 catalyses the 286 
addition of glutathione to the drug activated during phase I reactions with electrophiles (Shea 287 
et al., 1988a;McLellan and Wolf, 1999a).  288 
A more specific influence of non-coding RNAs on drug metabolism was demonstrated for 5-289 
fluorouracil in liver and colon tumours (Offer et al., 2014;Chai et al., 2015). 290 
Dihydropyrimidine dehydrogenase, an important enzyme in 5-fluorouracil metabolism, is 291 
repressed by miR-494 in colon tumours and by miR-27a as well as miR-27b in liver cancer 292 
(Offer et al., 2014;Chai et al., 2015). The fact that the translation of one and the same enzyme 293 
in two different tissues is under the control of different miRNAs underlines the tissue-specific 294 
regulation and fine-tuning of protein expression that is exerted by miRNAs.  295 
In liver cancer the translation of two of the most important targets of chemotherapeutic 296 
agents, dihydrofolate reductase and thymidylate synthase, are repressed by up-regulation of 297 
miR-215 (Wang et al., 2015b). Reduced expression of dihydrofolate reductase and 298 
thymidylate synthase leads to the development of insensitivity to doxorubicin treatment 299 
(Wang et al., 2015b). 300 
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Thymidylate synthase is the target of 5-fluoruracil therapy and this enzyme is down-regulated 301 
by increased expression of miR-192 and miR-215 in colon cancer patients (Boni et al., 2010). 302 
In this case altered microRNA expression results in down-modulation of the drug target and 303 
leads to therapy failure. In addition, miR-192 and miR-215 alter the cell-cycle control at 304 
multiple levels and prevent progression into the S-phase leading to 5-fluorouracil resistance 305 
(Boni et al., 2010).  306 
A similar case was observed in pancreatic tumours where RRM2 (ribonucleotide reductase 307 
regulatory subunit M2) the target of gemcitabine is under direct control of miR-211 and let-308 
7a (Bhutia et al., 2013;Maftouh et al., 2014). Decreased expression of miR-211 and let-7a 309 
results in higher RRM2 protein level and renders the tumours resistant to gemcitabine (Bhutia 310 
et al., 2013;Maftouh et al., 2014). 311 
 312 
Deregulation of cell-cycle, DNA repair pathways and alteration in death pathways 313 
Impaired cell cycle regulation and alteration of cell death pathways are common causes of   314 
drug resistance (Helleday et al., 2008;Rodrigues et al., 2012b). Increased cell cycle 315 
progression and reduced cell death rate lead to accumulation of mutations and uncontrolled 316 
cell proliferation, a hallmark of tumour cells (Hanahan and Weinberg, 2011). Errors in the 317 
DNA-damage response program pathways [nuclear excision repair (NER), base excision 318 
repair (BER), DNA mismatch repair (MMR)] play an important role in cancer progression 319 
and chemo-resistance (Hoeijmakers, 2001;Harper and Elledge, 2007;Jackson and Bartek, 320 
2009;Pearl et al., 2015). A complex interaction interplay exists between non-coding RNAs 321 
and the DNA-damage pathways: on one hand the DNA-damage pathway induces the 322 
expression of several non-coding RNAs especially of microRNAs and on the other hand non-323 
coding RNAs regulate directly the expression of several genes involved in DNA-damage 324 
pathway. This interaction is cell type specific and dependent on the intensity and nature of 325 
DNA damage (Pothof et al., 2009;Wouters et al., 2011;Chowdhury et al., 2013;Sharma and 326 
Misteli, 2013;Bottai et al., 2014).  327 
LncRNA HOTAIR (HOX transcript antisense RNA) is highly expressed in a broad variety of 328 
solid tumours including liver, colorectal, pancreatic and gastrointestinal stromal tumours 329 
(Geng et al., 2011;Kogo et al., 2011;Niinuma et al., 2012). LncRNA HOTAIR reprogram 330 
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chromatin organization together with the polycomb repressive complex PRC2 (Kogo et al., 331 
2011). Up-regulation of lncRNA HOTAIR results in higher expression level of members of 332 
the PRC2 complex (SUZ12, EZH2, and H3K27me3) (Kogo et al., 2011). Therefore, 333 
increased lncRNA HOTAIR expression is associated with a genome-wide reprogramming via 334 
PRC2 mediated epigenetic silencing of chromatin (Kogo et al., 2011). In addition lncRNA 335 
HOTAIR down-regulates cyclin-dependent kinase inhibitor 1 (p21(WAF/CIP1)) (Liu et al., 336 
2013) causing the loss of an important regulator of the  G1 and S phase progression (el-Deiry 337 
et al., 1993;Waldman et al., 1995;Bunz et al., 1998). Due to the fact that p21(WAF/CIP1) 338 
represents a major target of p53 activity DNA damage in lncRNA HOTAIR expressing 339 
tumour cells don´t go into cell cycle arrest and this promote cisplatin resistance (el-Deiry et 340 
al., 1993;Waldman et al., 1995;Bunz et al., 1998;Liu et al., 2013). 341 
In oesophageal, gastric, colorectal and hepatocellular cancer as well as cholangiocarcinomas, 342 
lncRNA TUG1 (taurine-up-regulated gene 1) is involved in causing resistance to 343 
chemotherapy (Huang et al., 2015;Dong et al., 2016;Jiang et al., 2016;Li et al., 2016b;Wang 344 
et al., 2016a;Zhang et al., 2016a;Xu et al., 2017c). In tumour tissue lncRNA TUG1 is up-345 
regulated and promotes cell growth by increased transcription of the Bcl-2 gene and 346 
epigenetic silencing of cyclin-dependent protein kinase inhibitors (p15, p16, p21, p27 and 347 
p57) and pro-apoptotic genes (caspase-3, caspase-9 and Bax) (Huang et al., 2015;Dong et al., 348 
2016;Jiang et al., 2016;Li et al., 2016b;Wang et al., 2016a;Zhang et al., 2016a;Xu et al., 349 
2017c). Therefore, lncRNA TUG1 is an excellent example for the fact that non-coding RNAs 350 
target simultaneously the expression of different genes; beside increasing the expression level 351 
of the anti-apoptotic protein Bcl-2, expression of key players in the caspase-mediated 352 
apoptosis pathway are inhibited together with different cyclin-dependent protein kinase 353 
inhibitors. This results in decreasing the G0/G1 arrest during cell cycle and reduces the 354 
apoptosis rate of the tumour cells. Most probably lncRNA TUG1 has also a role in the 355 
epithelial-mesenchymal transition (Wang et al., 2016a;Xu et al., 2017c) that increases 356 
resistance to drug treatments further as outlined in detail below. 357 
Also, the lncRNA PANDAR (promoter of CDKN1A antisense DNA damage-activated RNA) 358 
is often deregulated in different GI tumours like gastric, colorectal and hepatocellular cancer 359 
as well as cholangiocarcinoma (Peng and Fan, 2015;Ma et al., 2016a;Lu et al., 2017a;Xu et 360 
al., 2017b). In all these tumours up-regulation of lncRNA PANDAR results in increased 361 
I  revi
w
Non-coding RNAs and anticancer drugs
 
 
proliferation rate and reduced apoptosis (Peng and Fan, 2015;Ma et al., 2016a;Lu et al., 362 
2017a;Xu et al., 2017b). LncRNA PANDAR interacts with the transcription factor NF-YA, 363 
an important regulator for transcription of pro-apoptotic genes (Hung et al., 2011). This 364 
interaction between lncRNA PANDAR and NF-YA results in decreased expression of pro-365 
apoptotic genes and eventually leads to drug resistance (Peng and Fan, 2015;Ma et al., 366 
2016a;Lu et al., 2017a;Xu et al., 2017b). 367 
LncRNA UCA1 (urothelial carcinoma associated1) mediates resistance to doxorubicin 368 
treatment in gastric cancer (Shang et al., 2016). In in-vitro systems knockdown of lncRNA 369 
UCA1 overcomes the doxorubicin resistance due to an increased expression of PARP and 370 
reduced expression of Bcl-2 resulting in higher apoptosis rate (Shang et al., 2016).  371 
Furthermore, it was shown that lncRNA UCA1 sequesters miR-204-5p in colorectal cancer 372 
and reduces the level of this microRNA in cancer cells (Bian et al., 2016). The consequence 373 
is enhanced cell proliferation and 5-fluorouracil resistance (Bian et al., 2016). 374 
Another example of non-coding RNAs influencing cell-cycle is lncRNA ARA (adriamycin 375 
resistance associated) (Jiang et al., 2014;Cox and Weinman, 2016). LncRNA ARA was found 376 
to be over-expressed in doxorubicin resistant liver cancer cell lines compared to the parental 377 
cell lines (Jiang et al., 2014). Down-regulation of lncRNA ARA results in cell-cycle arrest in 378 
G2/M phase, suppressed proliferation, increased apoptotic cell death and, as expected, a 379 
reduced resistance against doxorubicin (Jiang et al., 2014;Cox and Weinman, 2016). 380 
Furthermore, lncRNA ARA is involved in the regulation of multiple signalling pathways 381 
including the MAPK-pathway (Jiang et al., 2014;Cox and Weinman, 2016). Beside lncRNA 382 
ARA the lncRNA URHC (up-regulated in hepatocellular carcinoma) is found among the 383 
most up-regulated lncRNAs in hepatocellular carcinoma. One target of lncRNA URHC is the 384 
tumour-suppressor ZAK (Xu et al., 2014b). Down-regulation of ZAK via lncRNA URHC 385 
results in increased cell proliferation and inhibits apoptosis (Xu et al., 2014b). 386 
In pancreatic cancer lncRNA HOTTIP (HOXA transcript at the distal tip) up-regulates the 387 
homeobox-transcription factor HOX13 resulting in de-regulation of the cell cycle as well as 388 
gemcitabine resistance (Wang et al., 2011;Li et al., 2015e).  389 
Down-regulation of lncRNA LOC285194 in oesophageal cancer results in resistance to 390 
chemoradiotherapy (radiation in combination with platinum- or paclitaxel-based 391 
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chemotherapy) by influencing cell-cycle progression and non-apoptotic cell death pathway 392 
via regulating VEGF receptor 1 (Tong et al., 2014). 393 
In contrast, lncRNA MALAT-1 is strongly over-expressed in oesophageal tumour tissue and 394 
binds miR-107 and miR-217 (Lin and Xu, 2015;Wang et al., 2015c). MiR-107 and miR-217 395 
decoy translates in reduced activity of the ATM-CHK2 signalling pathway leading to reduced 396 
cell-cycle arrest and cell death as response to DNA damage (Smith et al., 2010;Wang et al., 397 
2015c) and over-expression of the transcription factor B-Myb – an important regulator for 398 
G1/S and G2/M cell-cycle progression and cell survival (Lin and Xu, 2015;Wang et al., 399 
2015c).  400 
In addition, several microRNAs have been identified as regulators for cell cycle progression 401 
and induction of cell death pathways. Therefore, deregulated microRNA expression pattern is 402 
often a reason for drug resistance in GI tumours.  403 
Colorectal cancers with up-regulated mir-203 are resistant to oxaliplatin (Zhou et al., 2014). 404 
Failure of oxaliplatin therapy is caused by miR-203 mediated down-regulation of the 405 
important mediator protein for DNA damage response ATM (Zhou et al., 2014). As reaction 406 
to DNA damage, ATM induces the expression of DNA repair proteins, interrupts the cell 407 
cycle and induces cell death in the case of extended DNA damage (Choy and Watters, 2018). 408 
Oxaliplatin resistance can also be caused by up-regulation of miR-503-5p in colorectal cancer 409 
(Xu et al., 2017a). Increased expression of miR-503-5p results in down-regulation of the 410 
apoptotic protein PUMA (p53 upregulated modulator of apoptosis) and leads to resistance to 411 
oxaliplatin-induced apoptosis (Xu et al., 2017a). In colon cancer tissues down-regulation of 412 
miR-320 is linked to resistance to 5-fluorouracil therapy (Wan et al., 2015). Among the 413 
targets for miR-320 is the transcription factor SOX4 which is involved in inhibition of p53-414 
mediated apoptosis as well as the cell cycle regulators FOXM1 and FOXQ1 both known to 415 
have oncogenic potential (Wan et al., 2015;Vishnubalaji et al., 2016). 416 
In colorectal cancer cells miR-21 over-expression results in inhibition of the MMR proteins 417 
MSH2 and MSH6, two important proteins for DNA damage recognition and repair (Valeri et 418 
al., 2010a). Inhibition of MSH2 and MSH6 leads to reduced G2/M cell-cycle arrest caused by 419 
5-fluorouracil induced DNA damage and lower apoptosis rate in-vitro and in-vivo (Valeri et 420 
al., 2010a). Therefore, miR-21 over-expression reduces the therapeutic efficacy of 5-421 
fluorouracil-based chemotherapy in colorectal cancer treatment (Valeri et al., 2010a). 422 
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Furthermore, it was proven that the core mismatch repair proteins MSH2, MSH6 and MLH1 423 
are also down-regulated by miR-155 potentially contributing to drug resistance (Valeri et al., 424 
2010b). According to another study, 5-fluorouracil resistance in colorectal cancer cells can 425 
also be mediated by increased expression of miR-31 causing cell cycle deregulation and 426 
reduced apoptosis rate (Wang et al., 2010b;Cekaite et al., 2012). Efficacy of 5-fluorouracil 427 
treatment in colorectal cancer patients can also be limited due to up-regulation of anti-428 
apoptotic proteins like XIAP (X-linked inhibitor of apoptosis) and UBE2N (ubiquitin-429 
conjugating enzyme E2N) as a consequence of decreased miR-96 expression (Kim et al., 430 
2015) or due to up-regulation of the anti-apoptotic proteins Bcl-2, Bcl-2-like protein 11 431 
(BIM) or Bcl-2-like protein 2 (Bcl2L2) by reduced expression of miR-129, miR-10b or miR-432 
195, respectively (Nishida et al., 2012;Karaayvaz et al., 2013;Qu et al., 2015). In other colon 433 
cancer studies reduced expression levels of miR-365, miR-1915 and miR-34a have been 434 
described as reason for increased expression of BCL-2 (Wang et al., 2010a;Nie et al., 435 
2012;Xu et al., 2013).  436 
Increased Bcl-2 expression has been identified as a reason for resistance to 5-fluorouracil in 437 
other GI tumours, too, but the posttranscriptional regulation of mRNA coding for Bcl-2 is 438 
under the control of different miRNAs; e.g. in gastric cancer diminished expression of miR-439 
204 is the reason (Sacconi et al., 2012). According to another study up-regulation of Bcl-2 is 440 
caused by lower miR-15b and miR-16 expression level and leads to drug resistance in gastric 441 
cancer cells due to reduced apoptosis (Xia et al., 2008). MiR-25 over-expression was related 442 
to cisplatin resistance in gastric cancer cells (He et al., 2017). MiR-25 targets directly 443 
mRNAs coding for tumour suppressors like FOXO3a, ERBB2, FBXW7 (Zhao et al., 444 
2014a;Gong et al., 2015;Li et al., 2015a;He et al., 2017). All these proteins are involved in 445 
cell cycle regulation and apoptosis (Huang and Tindall, 2006;Nho and Hergert, 2014;He et 446 
al., 2017). Up-regulation of miR-223 targets FBXW7 (F-box/WD repeat-containing protein 447 
7) and leads to cell-cycle deregulation and cisplatin resistance in gastric tumours (Zhou et al., 448 
2015). Furthermore, up-regulation of miR-103/107 results in decreased expression of 449 
caveolin-1 in gastric cancer cells (Zhang et al., 2015d). The tumour suppressor caveolin-1 is a 450 
counter regulator for the Ras-p42/p44 MAP kinase pathway and due to the down-regulation 451 
by miR-103/107 increased activity of the Ras-p42/44 Map kinase pathway results in 452 
increased cell cycle progression and reduced cell death (Le Gall et al., 2000;Mebratu and 453 
Tesfaigzi, 2009). In gastric cancer increased cell cycle progression is also caused by 454 
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increased expression of miR-215 resulting in reduced expression of the tumour suppressor 455 
retinoblastoma 1, an important cell cycle regulator (Deng et al., 2014;Xu and Fan, 2015). Up-456 
regulation of miR-106a targets FAS and inhibits the extrinsic apoptotic pathway in gastric 457 
cancer (Xiao et al., 2009;Wang et al., 2013c). In turn, reduced amount of FAS leads to 458 
increased cell proliferation, reduced apoptosis rate and drug resistance (Xiao et al., 459 
2009;Wang et al., 2013c). 460 
Over-expression of miR-21 inhibits cell cycle arrest resulting in increased cell proliferation, 461 
reduced apoptotic rate, gemcitabine and 5-fluorouracil resistance in pancreatic cancer 462 
(Moriyama et al., 2009;Park et al., 2009;Donahue et al., 2014). Similarly, in other pancreatic 463 
cancer studies, miR-21 over-expression results in reduced level of PTEN and Bcl-2 leading to 464 
activation of AKT-mTOR pathway, reduced apoptosis and resistance against gemcitabine 465 
treatment (Giovannetti et al., 2010;Dong et al., 2011). Increased expression of miR-214 466 
represses directly ING4 in pancreatic tumour (Zhang et al., 2010). This impairs cell-cycle 467 
arrest, DNA repair as well as apoptosis and results in resistance to gemcitabine treatment 468 
(Zhang et al., 2010). The expression of the important pro-apoptotic protein BIM is reduced 469 
by miR-17-5p in pancreatic cancer and results in decreased apoptotic rate leading to 470 
resistance to gemcitabine treatment (Yan et al., 2012). Therapy failure is also caused by the 471 
repression of a tumour suppressor network involved in cell cycle and apoptosis regulation 472 
composed of PDCD4, BTG2 and NEDD4L by the combined action of miR-21, miR-23a and 473 
miR-27a (Frampton et al., 2014a;Frampton et al., 2014b). Furthermore, over-expression of 474 
miR-1246 results in decreased expression of cyclin-G2 and impairs the cell cycle regulation 475 
resulting in resistance to gemcitabine (Hasegawa et al., 2014). Recently miR-1307 was 476 
identified to be responsible for FOLFIRINOX resistance in pancreatic cancer (Carotenuto et 477 
al., 2018). MiR-1307 is up-regulated in in-vitro models of FOLFIRINOX resistant pancreatic 478 
cancer as well as in patient derived material compared to the surrounding tissue (Carotenuto 479 
et al., 2018). Reduced apoptosis rate and an extended acceptance of DNA damage seems to 480 
be the consequence of higher miR-1307 expression (Carotenuto et al., 2018).  481 
In hepatocellular carcinoma the liver specific miR-122 is down-regulated and as consequence 482 
the expression of the target gene CCNG1 is increased (Fornari et al., 2009). High level of 483 
cyclin G1 protein is found in several human tumours and results in reduced cell cycle control 484 
in the G2/M phase and modulation of p53 activity (Fornari et al., 2009;Xu et al., 2011). This 485 
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results in reduced DNA-repair and diminished apoptotic rate (Fornari et al., 2009;Xu et al., 486 
2011). As already mentioned above, ABC transporter proteins are highly expressed in liver 487 
tumours due to the missing post-transcriptional regulator miR-122 (Xu et al., 2011). All these 488 
effects caused by miR-122 down-regulation promote doxorubicin resistance in liver cancer 489 
patients (Fornari et al., 2009;Xu et al., 2011). Another reason for doxorubicin resistance in 490 
liver cancer is based on reduced expression of miR-26b (Fan et al., 2008). Among the miR-491 
26b targets in liver are the NF-ϰB activating proteins TAB3 and TAK1 (Fan et al., 2008;Zhao 492 
et al., 2014b). Therefore, a reduced expression of miR-26b results in increased activation of 493 
NF-ϰB and promotes drug resistance (Fan et al., 2008;Zhao et al., 2014b). Also, down-494 
regulation of miR-101 is described as reason for resistance to doxorubicin in hepatocellular 495 
carcinoma (He et al., 2016). The anti-apoptotic protein Mcl-1 is among the targets of miR-496 
101 and high levels of Mcl-1 renders liver tumour cells resistant to doxorubicin treatment (He 497 
et al., 2016). Furthermore, doxorubicin treatment failure in liver cancer patients has been 498 
connected to down-regulation of miR-199a-3p (Fornari et al., 2010). Besides targeting mTOR 499 
and c-Met, miR-199a-3p influences cell cycle regulation (Fornari et al., 2010). Decreased 500 
miR-199a-3p level results in down-regulation of the G1-checkpoint CDK inhibitors p21 501 
(CDKN1A) and p27 (CDKN1B) and abrogate the G1 arrest following damage to DNA 502 
(Abukhdeir and Park, 2008;Fornari et al., 2010). In another study down-regulation of the G1 503 
inhibitor CDKN1A in hepatocellular carcinoma was linked to up-regulation of miR-519d 504 
(Fornari et al., 2012). Consequently the apoptotic rate is reduced due to down-regulated miR-505 
199a-3p as well as up-regulated miR-519d expression (Fornari et al., 2010;Fornari et al., 506 
2012). 507 
 508 
Another important tumour suppressor protein involved in resistance to anti-cancer drugs is 509 
PTEN because it is a main regulator for PI3K-AKT-mTOR pathway which is often 510 
hyperactivated in cancer and is one of the drivers for tumour growth and survival (Khan et 511 
al., 2013;LoRusso, 2016). PTEN itself is regulated by different microRNAs in different GI 512 
tumours, e.g.by miR-21 in liver and gastric cancer, miR-22 in p53-mutated colon cancer and 513 
mir-17-5p in colorectal cancer (Meng et al., 2007;Li et al., 2011;Zhang et al., 2012;Yang et 514 
al., 2013a;Fang et al., 2014). In all cases up-regulation of microRNAs results in decreased 515 
PTEN level in the tumour cell and subsequent activation of AKT-mTOR pathways resulting 516 
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in resistance to cisplatin (gastric cancer), paclitaxel (p53-mutated colon tumour) and 517 
FOLFOX (colorectal cancer) (Meng et al., 2007;Li et al., 2011;Zhang et al., 2012;Yang et al., 518 
2013a;Fang et al., 2014). Down-regulation of PTEN due to over-expression of miR-19a and 519 
miR-19b in gastric cancer results in multi-drug resistance (Wang et al., 2013a). 520 
Furthermore, mTOR is an important regulator under physiological as well as pathological 521 
conditions. In p53 mutant colorectal cancer mTOR is down-regulated by miR-338-3p and 522 
results in resistance to 5-fluorouracil treatment (Han et al., 2017). Indeed, inhibition of miR-523 
338-3p in cell culture models restored sensitivity to 5-fluorouracil (Han et al., 2017) likely 524 
due to increased autophagy and reduced apoptosis following decrease in mTOR expression 525 
(Gonzalez et al., 2014;Han et al., 2017). 526 
Autophagy is a further mechanism for chemoresistance (Song et al., 2009;Huang et al., 527 
2016;Gozuacik et al., 2017;Xiong et al., 2017). In liver cancer up-regulation of lncRNA 528 
HULC activates autophagy by increasing the expression of ubiquitin-specific peptidase 22 529 
(USP22) which in turn prevents the ubiquitin-mediated degradation of silent information 530 
regulator 1 (SIRT1) by removing the conjugated polyubiquitin chains from SIRT1 (Xiong et 531 
al., 2017). Autophagy causes resistance to oxaliplatin, 5-fluorouracil and epitubicin 532 
treatments in liver tumours (Xiong et al., 2017). In addition, lncRNA HULC down-regulates 533 
the expression of microRNAs that target directly the 3´-UTR of USP22 (miR-6825-5p, miR-534 
6845-5p and miR-6886-3p) in liver cancer cells and prevents by this inhibition of USP22 at 535 
translational level (Xiong et al., 2017). 536 
LncRNA MALAT-1 is highly expressed in gastric cancer cells resistant to 5-fluoruracil and 537 
cis-platin, respectively, compared to parental gastric cancer cells (YiRen et al., 2017). 538 
LncRNA MALAT-1 quenches miR-23b-3p and subsequently increases the expression of 539 
ATG12, an important regulator of autophagy (YiRen et al., 2017). 540 
In oxaliplatin resistant colon cancer miR-409-3p is down-regulated so that the direct target 541 
Beclin-1 is expressed and induces autophagy (Tan et al., 2016). Over-expression of miR-409-542 
3p results in low autophagic activity and overcomes oxaliplatin resistance in model systems 543 
of colon cancer (Tan et al., 2016). 544 
 545 
Induction of epithelial-mesenchymal transition 546 
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Drug resistance can be caused by epithelial-mesenchymal transition (EMT) (Bedi et al., 547 
2014;Heery et al., 2017). Several EMT-related signalling pathways are well known to be 548 
involved in mediating drug resistance in tumours (Nurwidya et al., 2012;Housman et al., 549 
2014;Du and Shim, 2016;Heery et al., 2017). Cells undergoing EMT have several features in 550 
common with cancer stem cells (e.g. increased drug efflux pumps and anti-apoptotic effects) 551 
and furthermore EMT is instrumental for generation and maintenance of cancer stem cells 552 
(Housman et al., 2014;Du and Shim, 2016;Heery et al., 2017). 553 
The lncRNA PVT1 (plasmacytoma variant translocation 1) has been found to be elevated in 554 
nearly all GI tumours including gastric, oesophageal, pancreatic, colon and liver cancers 555 
(Zheng et al., 2016;Wu et al., 2017;Zeng et al., 2017;Zhou et al., 2017). Increased expression 556 
of lncRNA PVT1 results in EMT and drug resistance (Zheng et al., 2016;Wu et al., 557 
2017;Zhou et al., 2017). 558 
The tumour suppressor lncRNA LEIGC prevents normal cells to undergo EMT. Therefore, 559 
the reduced expression of lncRNA LEIGC in gastric cancer fosters EMT and results in 560 
resistance to 5-fluorouracil treatment (Han et al., 2014b;Fang et al., 2015).  561 
Up-regulation of lncRNA HULC has been correlated to induced EMT and suppressed 562 
apoptosis in gastric tumours leading to cisplatin resistance (Zhao et al., 2014c;Zhang et al., 563 
2016b). 564 
Increased expression of lncRNA-ATB (lncRNA-activated by TGF-β) in liver cancer results 565 
in competition with members of the miR-200 family for binding sites in the 3´-UTR of 566 
mRNAs coding for the transcription factors ZEB1 and ZEB2 (Yuan et al., 2014). In turn, 567 
high expression of ZEB1 and ZEB2 causes EMT and increased drug resistance (Yuan et al., 568 
2014).  569 
In pancreatic cancer the lncRNA MALAT-1 is a regulator of EMT (Ying et al., 2012;Jiao et 570 
al., 2014). In addition, the lncRNA MALAT-1 suppress G2/M cell cycle arrest and apoptosis 571 
leading to resistance to gemcitabine treatment (Jiao et al., 2014). As demonstrated by this 572 
example, the same lncRNA can induce resistance to chemotherapy by regulating different 573 
mechanisms at the same time.  574 
Induction of EMT and resistance to gemcitabine treatment in pancreatic cancer cells can also 575 
be caused by miR-223 over-expression (Ma et al., 2015). Inhibition of miR-223 restored the 576 
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sensitivity of pancreatic cancer cell lines to gemcitabine treatment (Ma et al., 2015). 577 
Similarly, gemcitabine resistance in pancreatic cancer can also be caused by down-regulation 578 
of microRNAs as demonstrated for miR-200 (miR-200a, miR-200b and miR-200c) and let-7 579 
family resulting in EMT (Li et al., 2009;Yu et al., 2010).  580 
In colon cancer cells down-regulation of miR-147 results in EMT and increases the 581 
phosphorylation rate of AKT (Lee et al., 2014). Beside the activation of the PI3K-AKT 582 
pathway, the lower expression level of miR-147 also activates the TGF-β pathway and 583 
eventually leads to resistance to gefitinib treatment (Lee et al., 2014). Increased expression of 584 
miR-224 in colon cancer tissue was identified as another reason for resistance to 5-585 
fluorouracil treatment. Increased miR-224 expression translates in increasing phosphorylation 586 
rate of extracellular signal-regulated kinase (ERK) and AKT, resulting in activation of both 587 
pathways (Amankwatia et al., 2015). In addition, miR-224 seems to activate also EGFR 588 
dependent- and NF-ϰB-signalling pathway leading to EMT (Amankwatia et al., 2015). 589 
 590 
Cancer cell stemness 591 
A further reason for drug resistance is the presence of cancer stem cells. Cancer stem cells are 592 
well known for being refractory to chemotherapies and therefore cause therapy failure and 593 
tumour recurrence or progression (Reya et al., 2001;Ischenko et al., 2010;Li et al., 594 
2010;Shankar et al., 2011;Srivastava et al., 2011;Nguyen et al., 2012;Pattabiraman and 595 
Weinberg, 2014). Once again non-coding RNAs especially lncRNAs and microRNAs are 596 
involved in sustaining the cancer stem cell niche (Tay et al., 2008;Liu and Tang, 2011;Sun et 597 
al., 2014;Garg, 2015;Chen et al., 2017).  598 
The lncRNA UCA1 (urothelial carcinoma associated 1; identical with lncRNA CUDR 599 
(cancer up-regulated drug resistant)) is strongly expressed in different tumours; among these,  600 
gastric, hepatocellular,  pancreatic, colorectal cancers and oesophageal squamous cell 601 
carcinoma (Han et al., 2014a;Li et al., 2014b;Wang et al., 2015a;Chen et al., 2016;Shang et 602 
al., 2016;Chen et al., 2017;Li et al., 2017;Wang et al., 2017). LncRNA UCA1 binds to 603 
several microRNAs in different tumours (e.g. miR-216b in liver cancer, miR-204 in 604 
oesophageal and colon cancer, miR-27b in gastric cancer) and influences entire 605 
transcriptional programs as well as response towards therapy (Wang et al., 2015a;Bian et al., 606 
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2016;Fang et al., 2016b;Jiao et al., 2016;Wang et al., 2017). Well-established up-regulated 607 
targets of lncRNA UCA1 are members of the Wnt-ß-catenin signalling pathway, several 608 
transcription factors and cell division regulators (Wang et al., 2008;Li and Chen, 2016). For 609 
cell stem cells the Wnt-ß-catenin pathway is of pivotal importance for cell self-renewal and 610 
mediating drug resistance (Taipale and Beachy, 2001;Fan et al., 2014a). Over-expression of 611 
lncRNA UCA1 results in resistance to cancer treatments with tamoxifen, 5-fluorouracil, 612 
gemcitabine, cisplatinum, doxorubicin, imatinib and tyrosine-kinase inhibitors targeting 613 
EGFR (Bian et al., 2016;Shang et al., 2016;Li et al., 2017;Wang et al., 2017).  614 
Silencing of lncRNA UCA1 in in-vitro and in-vivo systems proved the oncogenic role of 615 
lncRNA UCA1 in gastric cancer (Shang et al., 2016;Li et al., 2017). Reduced expression 616 
level of lncRNA UCA1 results in reduced proliferation rate, increased apoptosis rate and 617 
overcomes the resistance to doxorubicin (Shang et al., 2016;Li et al., 2017). Furthermore, 618 
lncRNA UCA1 is a direct regulator of the PI3K-AKT-mTOR pathway (Li et al., 2017) which 619 
is often found to be deregulated in human cancers and is known to contribute to chemo-620 
resistance of cancer cells (Xia and Xu, 2015;Safa, 2016). In another study over-expression of 621 
lncRNA UCA1 was shown to cause reduced miR-27 expression causing diminished 622 
apoptosis of gastric cancer cells due to increased Bcl-2 protein level in combination with 623 
reduced cleaved caspase-3 (Fang et al., 2016b). This results in multidrug resistance of gastric 624 
tumours (Fang et al., 2016b). 625 
Over-expression of lncRNA UCA1 is also a reason for chemo-resistance against 5-626 
fluorouracil treatment in colon cancer (Bian et al., 2016). LncRNA UCA1 causes resistance 627 
by binding miR-204-5p and consequently up-regulating the expression of its target genes Bcl-628 
2, RAB22A and CREB1 (Bian et al., 2016). MiR-21 was identified as an important player in 629 
regard to failure of 5-fluorouracil therapy in colon cancer patients (Yu et al., 2013). Mir-21 is 630 
able to increase the number of undifferentiated cancer stem cells during 5-fluorouracil 631 
treatment and contributes by this to therapy failure (Yu et al., 2013).  632 
In liver cancer lncRNA UCA1 contributes to chemotherapy resistance and malignant 633 
transformation of hepatocyte-stem cells (Gui et al., 2015;Li and Chen, 2016;Li et al., 634 
2016a;Chen et al., 2017;Huang et al., 2017;Zheng et al., 2017). LncRNA UCA1 increases 635 
directly the transcription rate of the oncogene c-myc well known to be involved in drug 636 
resistance as well as in activating stem-cell like properties in hepatocarcinoma (Walker et al., 637 
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1996;Lin et al., 2007;Pyndiah et al., 2011;Akita et al., 2014;Pu et al., 2015). Furthermore, 638 
lncRNA UCA1 also induces the expression of lncRNA HULC (highly up-regulated in liver 639 
cancer) in liver cancer and lncRNA HULC in turn stimulates the activity of the Wnt-ß-640 
catenin pathway (Gui et al., 2015). In addition, lncRNA UCA1 forms a complex with the 641 
cell-cycle regulator cyclin-D which enhances the expression of lncRNA H19 by inhibiting the 642 
methylation of the lncRNA H19 promoter (Pu et al., 2015;Chen et al., 2017). High level of 643 
lncRNA H19 induces the telomerase activity and enhances the length of telomere thereby 644 
supporting the stem cell properties (Hiyama and Hiyama, 2007;Pu et al., 2015;Wu et al., 645 
2016b). Another effect of lncRNA UCA1 is the enhanced phosphorylation of the tumour 646 
suppressor retinoblastoma protein 1(RB1). RB1 phosphorylation results in increased cell 647 
cycle progression and in interaction of the phosphorylated retinoblastoma protein 1 with the 648 
SET1A complex. Such interaction catalyses the transcription-activating methylation of 649 
histone H3 lysine-4 on several gene promoters including telomeric repeat-binding factor 2 650 
promoter an important component for the telomerase extension process (Fang et al., 2016a;Li 651 
et al., 2016a).  652 
In liver cancer as well as in pancreatic, gastric, oesophageal and colon cancers a critical role 653 
in inducing the transformation of stem cells into cancer stem cell has been demonstrated for 654 
lncRNA HOTAIR (Chen et al., 2013;Endo et al., 2013;Kim et al., 2013;He et al., 655 
2014;Mohamadkhani, 2014;Li et al., 2015b;Chen et al., 2017). LncRNA HOTAIR is a strong 656 
activator for expression of OCT4, RNF51, CD44 and CD133 genes – all these proteins are 657 
involved in reprogramming the gene network to acquire cancer stem cell properties (Padua 658 
Alves et al., 2013;Zhu et al., 2014). LncRNA HOTAIR expression causes resistance against 659 
cisplatin and doxorubicin treatment in liver cancer model systems (Yang et al., 2011)  and 660 
renders gastric tumours resistant to cisplatin therapy by binding miR-126 and activating the 661 
PI3K-AKT-mTOR pathway (Yan et al., 2016). In the context of several GI cancer stem cells 662 
it has been shown that lncRNA HOTAIR down-regulates the expression of histone 663 
methyltransferase SETD2 and reduces the phosphorylation rate of SETD2 resulting in 664 
reduced trimethylation of histone H3 lysine-36 on several gene promoter, e.g. Wnt inhibitory 665 
factor-1 (WIF-1) (Ge et al., 2013;Kim et al., 2013;Ding et al., 2014;Li et al., 2015b). Reduced 666 
WIF-1 expression leads to activation and increased signalling through the Wnt-ß-catenin 667 
pathway (Ge et al., 2013;Kim et al., 2013). Furthermore, the modulated chromatin 668 
organisation account for a reduced efficiency of the mismatch repair system and damaged 669 
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DNA can escape from corrections leading to microsatellite instability (MSI) and altered 670 
expression of cell cycle regulators as well as reduced apoptosis (Gupta et al., 2010;Valeri et 671 
al., 2010b;Chen et al., 2013;Li et al., 2013;Li et al., 2015b). In addition, lncRNA HOTAIR 672 
induces accumulation of replication errors by hindering the complex formation of MSH2 with 673 
MSH6; one essential dimer for DNA mismatch recognition and repair (Yang et al., 674 
2004;Valeri et al., 2010a;Valeri et al., 2010b;Edelbrock et al., 2013;Pfister et al., 2014).  675 
In pancreatic cancer the oncogenic lncRNA MALAT-1 (metastasis-associated lung 676 
adenocarcinoma transcript-1) contributes to the expression of the cancer stem cell marker 677 
CD133, CD44, CD24 and aldehyde-dehydrogenase (Fan et al., 2014b;Jiao et al., 2014;Jiao et 678 
al., 2015). In addition, the expression of the core pluripotent factors OCT4, NANOG and 679 
SOX2 are also under the control of lncRNA MALAT-1 (Jiao et al., 2015). LncRNA linc-680 
ROR inhibits the expression of p53 and activates by this the transcription factor ZEB1 in 681 
pancreatic cancer (Wellner et al., 2009). ZEB1 in turn suppress the expression of the miR-682 
200 family that leads to maintenance of pancreatic cancer stemness and induces EMT known 683 
to be responsible for paclitaxel resistance in pancreatic cancer patients (Wellner et al., 684 
2009;Kim, 2017). Down-regulation of miR-205 results in increased expression of stem cell 685 
markers OKT3, OKT8 and CD44 in pancreatic cancer tissue and is linked to gemcitabine 686 
resistance (Singh et al., 2013). Re-expression of miR-205 is able to overcome the 687 
gemcitabine resistance in pancreatic cancer model systems (Singh et al., 2013). 688 
The lncRNA-34a mediates an increase in self-renewal of colon cancer stem cells and induce 689 
Wnt as well as NOTCH signalling pathways via sequester miR-34a expression (Bu et al., 690 
2013;Evans et al., 2015). 691 
In hepatocellular carcinoma the lncRNA linc-ROR (long intergenic ncRNA regulator of 692 
reprogramming) is involved in regulating core pluripotent factors (OCT-4, NANOG, SOX2) 693 
necessary for the stem cell like phenotype and causes resistance to chemotherapy (Takahashi 694 
et al., 2014). LncRNA linc-ROR competes with miR-145 for the same binding sites present 695 
in the mRNAs coding for OCT-4, NANOG and SOX2 (Wang et al., 2013b). Presence of 696 
lncRNA linc-ROR prevents the binding of miR-145 to the mRNA of the core pluripotent 697 
factors resulting in translation of these mRNAs and maintains the stem cell phenotype (Wang 698 
et al., 2013b). Furthermore, the expression of CD133, another cancer stem cell marker, is 699 
directly induced by lncRNA linc-ROR (Takahashi et al., 2014).  700 
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MiR-130b is connected to cancer stem cells growth in liver tumours (Ma et al., 2010). 701 
Increased expression of miR-130b targets directly the mRNA coding for tumour protein 53-702 
induced nuclear protein 1 and reduces the expression level of the corresponding protein (Ma 703 
et al., 2010). Furthermore, high level of miR-130b renders liver tumour cells resistant to 704 
doxorubicin treatment (Ma et al., 2010). Another reason for doxorubicin resistance in liver 705 
cancer patients is down-regulation of the tumour suppressor miR-101 resulting in increased 706 
protein expression of enhancer of zeste homolog 2 (EZH2) (Sasaki et al., 2008;Xu et al., 707 
2014a). EZH2 is a histone-lysine N-methyltransferase enzyme that silence Wnt-pathway 708 
antagonists and other tumour suppressor genes on the transcriptional level by histone 709 
methylation (Cheng et al., 2011). Over-expression of EZH2 is positively correlated with 710 
increased Wnt-ß-catenin signalling (Cheng et al., 2011). 711 
MiR-221 is over-expressed in 5-fluorouracil resistant oesophageal tumours (Wang et al., 712 
2016b). The mechanisms of resistance is mediated via down-regulation of the direct target 713 
DDK2 (dickkopf-related protein 2) and subsequent activation of the Wnt-ß-catenin pathway 714 
(Wang et al., 2016b). Furthermore, increased miR-221 expression fosters EMT and facilitates 715 
the formation of tumour stem cells (Wang et al., 2016b). 716 
In colon cancer stem cells, miR-451 was found to be down-regulated compared to colon 717 
cancer cells (Bitarte et al., 2011). Reduced level of miR-451 seems to be essential for the 718 
self-renewal of colon cancer stem cells (Bitarte et al., 2011). In addition, expression of 719 
ABCB1 transporter is increased in colon cancer stem cells due to lack of miR-451 post-720 
transcriptional down-regulation resulting in resistance to irinotecan treatment (Bitarte et al., 721 
2011).  722 
MiR-1182 is often down-regulated in gastric cancer tissue (Zhang et al., 2015a). One direct 723 
target of miR-1182 is telomerase reverse transcriptase (hTERT), an enzyme that is involved 724 
in controlling the length of telomere. Over-expression of hTERT due to missing 725 
transcriptional regulation by miR-1182, results in cell immortality and stem-cell property of 726 
gastric cancer cells (Zhang et al., 2015a). 727 
 728 
Targeted therapies and drug resistance 729 
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For GI cancer several targeted therapies exist (Table 3) (Jonker et al., 2007;Weber and 730 
McCormack, 2008;Loupakis et al., 2010;Roukos, 2010;Grothey et al., 2013;Muro et al., 731 
2015;King et al., 2017). They are used alone or in combination with chemotherapy. 732 
Unfortunately in most cases the patients develop resistance also against these targeted 733 
therapies and the above outlined general principles of drug resistance based on non-coding 734 
RNA dysregulation are involved. Beside that non-coding RNAs interfering with the targeted 735 
protein itself or (up-)regulating the targeted signal pathway are involved in drug resistance 736 
(Roukos, 2010). Furthermore, therapy failure can be related to activation of alternative signal 737 
pathways by non-coding RNAs (Roukos, 2010;Lu et al., 2017b). 738 
Recently it was demonstrated that resistance to cetuximab in colon cancer patients and in in-739 
vitro 3-D-cell culture models can be caused by over-expression of lncRNA MIR100HG (Lu 740 
et al., 2017b). Two microRNAs, miR-100 and miR-125b, are generated from lncRNA 741 
MIR100HG and these microRNAs down-regulate in a concerted way five negative regulators 742 
of the Wnt/ß-catenin pathway resulting in increased Wnt signalling (Lu et al., 2017b). This 743 
kind of cetuximab resistance can be overcome by inhibition of Wnt signalling, underscoring 744 
the potential clinical relevance of the interactions between EGFR and Wnt/ß-catenin 745 
pathways (Lu et al., 2017b). Increased mir-125b expression is also correlated with 746 
trastuzumab resistance in HER2-positive gastric cancer patients but up to now the molecular 747 
basis for this resistance is unclear (Sui et al., 2017). Sorafenib resistance in hepatocellular 748 
carcinoma is caused by lncRNA TUC338 (Jin et al., 2017). RASAL-1 (RAS protein activator 749 
like-1) is a direct target of lncRNA TUC338 and high expression of lncRNA TUC338 750 
inhibits the RASAL-1 expression resulting in activation of RAS-signalling (Jin et al., 2017). 751 
According to another in-vitro study, reduced expression of miR-193b leads to higher 752 
expression of the anti-apoptotic protein Mcl-1 and renders hepatocellular carcinoma cells 753 
resistant to sorafenib treatment (Braconi et al., 2010). 754 
 755 
Non-coding RNAs as potential biomarkers of resistance and novel therapeutics: promises 756 
and hurdles 757 
Our review summarises most of the current evidence supporting the role of non-coding RNAs 758 
in resistance to chemotherapy and targeted agents. It is likely that, in the near future, given 759 
the promising and exciting results obtained with the use of immunotherapy in 760 
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gastroesophageal (Kang et al., 2017) and colorectal cancer (Le et al., 2017;Overman et al., 761 
2018), new data will emerge on the already known regulation of PD-1, PD-L1 and CTLA-4 762 
by non-coding RNAs and response to nivolumab and pembrolizumab (Cortez et al., 2016;Xu 763 
et al., 2016;Smolle et al., 2017).  764 
The contribution of non-cording RNAs in resistance mechanisms to a broad range of anti-765 
cancer treatments makes their use as biomarkers or novel therapeutics quite promising but 766 
several challenges remain.    767 
Given microRNAs and, to a lesser extent, other non-coding RNAs can be reliably detected in 768 
tissues and bio-fluids such as plasma, serum and urine, it is tempting to hypothesize the use 769 
of non-coding RNA based tools to predict and monitor resistance to anticancer treatments. 770 
Few studies have already tested the validity of microRNAs as biomarkers of response to 771 
anticancer treatment in other cancers such as prostate (Lin et al., 2017), chronic lymphocytic 772 
leukaemia (Gagez et al., 2017) and sarcomas (Wiemer et al., 2017). In colorectal cancer, we 773 
(Sclafani et al., 2015) and others (Graziano et al., 2010;Zhang et al., 2011;Sha et al., 2014)  774 
have tested the contribution of a single nucleotide polymorphism (SNP) in the binding site of 775 
let-7 in the KRAS 3’UTR in predicting benefit from anti-EGFR treatment with conflicting 776 
results across different trials. Despite the good reproducibility of the assay, the predictive 777 
value of the test was not confirmed in all trials likely due to use of cetuximab in different 778 
context (neo-adjuvant, adjuvant and metastatic colorectal cancer, respectively). Similarly the 779 
analysis of a SNP in miR-608 led to contradicting results in patients treated with neo-780 
adjuvant or adjuvant chemo- and radiochemo-therapy in colon and rectal cancers highlighting 781 
some of the challenges in validating data obtained in retrospective series (Lin et al., 782 
2012;Xing et al., 2012;Pardini et al., 2015;Sclafani et al., 2016). Tissue (cancer versus 783 
stroma) and organ (colon versus rectum) specificity in non-coding RNA expression might 784 
represent potential explanations for different findings obtained in some of these studies.  785 
Beside SNPs, expression of microRNAs can be detected in fresh frozen or formalin fixed 786 
paraffin embedded tissues and serve as potential biomarker of sensitivity or resistance to 787 
treatment. Robust data have emerged from the retrospective analysis of a prospective phase 788 
III clinical trial (Laurent-Puig et al., 2016). In this study, KRAS wild-type patients were 789 
classified based on high or low miR-31-3p expression: patients with high expression were 790 
resistant to cetuximab while patient with low expression had good and durable responses 791 
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which translated in survival benefit. The miR-31 expression cut-off for the classification into 792 
high or low expression was predefined in the above study. However, one of the key 793 
challenges in validating these interesting findings will be design of a clinically approved 794 
assay that can accurately assign patients into one of these two categories. In this prospective, 795 
the use of different sources of material (i.e. primary colorectal cancer versus metastasis) 796 
might result in different basal expression of the microRNA and as such different scoring. 797 
Source of material and choice of reference controls represent important obstacles that might 798 
bias the definition of a threshold for high or low expression of microRNAs in tissues and bio-799 
fluids. MicroRNAs can be detected in plasma, serum and urine samples and have been used 800 
for early detection and prognostic purposes in gastrointestinal cancer (Schultz et al., 801 
2014;Shigeyasu et al., 2017;Ozawa et al., 2018). The use of digital droplet approaches allows 802 
the quantitative detection of copies of the microRNA of interest based on the starting volume 803 
of bio-fluids and, potentially overcomes or at least mitigates, the issues related to the 804 
normalization of data against reference controls, making the definition of cut-off easier to 805 
standardize. One study has reported the potential role of miR-126 in predicting and tracking 806 
response to chemotherapy and anti-VEGF treatment in colorectal cancer (Hansen et al., 2015) 807 
and, with the advent of digital quantitative technologies, more studies are expected. 808 
In consideration of their role in cancer initiation, progression and resistance to treatment, 809 
non-coding RNAs and among them microRNAs have been proposed as potential therapeutics 810 
(Adams et al., 2017). A large body of pre-clinical evidence is available on the use of anti-811 
microRNAs or molecules re-expressing microRNAs alone or in combination with other 812 
agents in order to increase efficacy and prevent or revert drug resistance (Rupaimoole and 813 
Slack, 2017).  Inhibition of microRNAs has been tested in clinical trials in the context of 814 
HCV infection (Janssen et al., 2013;van der Ree et al., 2017) and in mesothelioma (van 815 
Zandwijk et al., 2017). These trials highlighted a huge potential for microRNA-based 816 
therapeutics but at the same time pinpointed some of the criticalities in further clinical 817 
development of such approaches. MiR-122 inhibition led to durable viral load reduction in 818 
both HCV trials and was associated with manageable side effects. Similarly, in mesothelioma 819 
patients treated with miR-16-loaded minicells the disease control rate was satisfactory and the 820 
toxicity profile acceptable warranting further investigations. Overall in both approaches the 821 
risk of off-target effects represent the main hurdle to be taken into account: indeed miR-122 822 
inhibition has been associated with risk of developing liver cancer in pre-clinical models 823 
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(Hsu et al., 2012) and, similarly, over-expression of miR-16 might lead to uncontrolled 824 
cardiac effects as proven in the phase I trial (van Zandwijk et al., 2017). These effects might 825 
be increased in combination studies in which anti-microRNAs or microRNA-conjugates are 826 
delivered together with chemotherapy leading to cumulative side effects. Therefore a robust 827 
understanding of the biology underpinning microRNA deregulation in physiology and 828 
pathological conditions in order to implement effort that can minimise the risk of serious 829 
adverse events hampering the clinical development of microRNA-based strategies.   830 
 831 
Conclusion: 832 
Non-coding RNAs especially lncRNAs and microRNAs are important mediators for drug 833 
resistance. They function in an organ and tissue specific manner and through different 834 
molecular mechanisms. One non-coding RNA always have several targets and in the end 835 
deregulation of one non-coding RNA alters the expression level of several proteins in a tissue 836 
specific way. For example, in the case of miR-374b more than 700 genes have been identified 837 
as direct target in pancreatic tissue (Schreiber et al., 2016). Drug resistance is a dynamic 838 
process caused by several cell and non-cell autonomous mechanisms. Given non-coding 839 
RNAs can simultaneously control several cancer-associated pathways, non-coding RNA 840 
dysregulation plays a crucial role in treatment resistance. Future studies will continue to shed 841 
insights in the fine interplay among lncRNA, microRNA and their target genes and might 842 
provide opportunities for more effective strategies to prevent or overcome resistance. In the 843 
interim, given non-coding RNAs and especially microRNAs can be tested in tissues and 844 
biofluids in a rapid, cost/effective and robust way. More investigational studies should 845 
explore their utility to monitor and forecast treatment response and resistance in order to 846 
personalise treatments and improve patient’s outcomes. 847 
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Figure legends: 855 
Figure 1: Role of non-coding RNAs for the different reasons that can cause resistance to 856 
anticancer drugs in liver cancer. For details about target genes and regulated protein 857 
expression by the non-coding RNAs see text. 858 
Figure 2: Role of non-coding RNAs for the different reasons that can cause resistance to 859 
anticancer drugs in oesophageal cancer. For details about target genes and regulated 860 
protein expression by the non-coding RNAs see text. 861 
Figure 3: Role of non-coding RNAs for the different reasons that can cause resistance to 862 
anticancer drugs in gastric cancer. For details about target genes and regulated protein 863 
expression by the non-coding RNAs see text. 864 
Figure 4: Role of non-coding RNAs for the different reasons that can cause resistance to 865 
anticancer drugs in colon and colorectal cancer. For details about target genes and 866 
regulated protein expression by the non-coding RNAs see text. 867 
Figure 5: Role of non-coding RNAs for the different reasons that can cause resistance to 868 
anticancer drugs in pancreatic cancer. For details about target genes and regulated protein 869 
expression by the non-coding RNAs see text. 870 
Figure 6: Role of non-coding RNAs for the different reasons that can cause resistance to 871 
anticancer drugs in gastrointestinal stromal cancer. For details about target genes and 872 
regulated protein expression by the non-coding RNAs see text. 873 
Figure 7: Role of non-coding RNAs for the different reasons that can cause resistance to 874 
anticancer drugs in cholangiocarcinoma. For details about target genes and regulated 875 
protein expression by the non-coding RNAs see text. 876 
  877 
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Table1: Overview about non-coding RNAs involved in resistance to anticancer drugs in 878 
gastrointestinal tumours. 879 
Abbreviation used: GI=gastrointestinal; vRNA=vault RNA; lncRNA=long non-coding RNA; 880 
miR=microRNA; EMT=epithelial-mesenchymal transition  881 
 882 
Non-coding 
RNA 
GI cancer type Causing drug resistance via Reference 
lncRNA 
AK022798 
gastric cancer increasing the expression of 
ABCB1 gene 
(Hang et al., 2015) 
lncRNA ANRIL gastric cancer increasing the expression of 
MDR1 gene 
(Zhang et al., 
2015c;Lan et al., 
2016) 
lncRNA ARA liver cancer reduced G2/M cell-cycle 
arrest; reduced apoptosis rate; 
de-regulation of MAPK-
pathway 
(Jiang et al., 
2014;Cox and 
Weinman, 2016) 
lncRNA-ATB liver cancer increased expression of ZEB1 
and ZEB2; induced EMT 
(Yuan et al., 2014) 
lncRNA CCAL colorectal cancer increasing the expression of 
ABCB1 gene; increased 
activity of Wnt/ß-catenin 
pathway 
(Ma et al., 2016b) 
lncRNA H19 liver cancer  
oesophageal cancer 
up-regulation of membrane 
glycoprotein p95; elevating 
the expression of MDR1 gene 
by increasing promoter 
methylation; increasing 
telomere length 
(Hiyama and 
Hiyama, 
2007;Tsang and 
Kwok, 
2007;Matouk et 
al., 2013) 
lncRNA 
HOTAIR 
liver cancer  
colorectal cancer  
pancreatic cancer  
GI stromal tumour 
increased expression of 
PRC2 complex members; 
genome-wide changes in 
transcription process due to 
epigenetic chromatin 
silencing; down-regulation of 
p21(WAF/CIP1); repression 
of G1/S cell-cycle arrest; 
increased proliferation rate; 
reduced DNA-damage 
response 
(el-Deiry et al., 
1993;Geng et al., 
2011;Kogo et al., 
2011;Liu et al., 
2013) 
lncRNA 
HOTAIR 
colon cancer  
pancreatic cancer  
gastric cancer  
transformation of stem cells 
into cancer stem cells due to 
activation of OCT4, RNF51, 
(Yang et al., 
2004;Edelbrock et 
al., 2013;Ge et al., 
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oesophageal cancer CD44 and CD133 gene 
expression; increased activity 
of Wnt/ß-catenin pathway; 
modulation of chromatin 
organisation leads to reduced 
efficiency of the mismatch 
repair system; increased MSI; 
reduced apoptosis rate; 
inhibition of the expression 
of miR-126 and activating the 
PI3K-AKT-mTOR pathway 
(in gastric cancer) 
2013;Kim et al., 
2013;Padua Alves 
et al., 2013;Zhu et 
al., 2014;Yan et 
al., 2016) 
lncRNA 
HOTTTIP 
pancreatic cancer increased expression of 
transcription factor HOX13; 
cell cycle deregulation 
(Wang et al., 
2011;Li et al., 
2015e) 
lncRNA HULC liver cancer increased activity of Wnt-ß-
catenin; increased expression 
of USP22 and SIRT1; 
reduced expression of miR-
6825-5p, miR-6845-5p, miR-
6886-3p; increased 
autophagy pathway 
(Xiong et al., 
2017) 
lncRNA HULC gastric cancer induced EMT; suppressed 
apoptosis  
(Zhao et al., 
2014c;Zhang et 
al., 2016b) 
lncRNA LEIGG gastric cancer induced EMT (Han et al., 
2014b;Fang et al., 
2015) 
lncRNA linc-
ROR 
pancreatic cancer inhibition of p53; inhibition 
of the expression of miR-200 
family; increased expression 
of the transcription factor 
ZEB1; induced EMT 
(Wellner et al., 
2009;Kim, 2017) 
lncRNA linc-
ROR 
liver cancer preventing the binding of 
miR-145 to pluripotent 
factors OKT-4, NANOG and 
SOX2 resulting in increased 
expression of these 
transcription factors 
necessary for sustain stem 
cell character 
(Wang et al., 
2013b;Takahashi 
et al., 2014) 
lncRNA 
LOC285194 
oesophageal cancer cell-cycle deregulation; 
blocking non-apoptotic cell 
death pathway  
(Tong et al., 2014) 
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lncRNA 
MALAT-1 
oesophageal tumour binds miR-107 and miR-217; 
reduced activity of the ATM-
CHK2 signalling pathway; 
reduced cell-cycle arrest and 
cell death as response to 
DNA damage; increased 
expression of transcription 
factor B-Myb  
(Smith et al., 
2010;Lin and Xu, 
2015;Wang et al., 
2015c) 
lncRNA 
MALAT-1 
pancreatic cancer increased expression of 
cancer stem cell marker 
CD133; increased expression 
of pluripotent factors OCT4, 
NANOG and SOX2;  
induced EMT; repression of 
G2/M cell-cycle arrest; 
reduced apoptosis rate 
(Ying et al., 
2012;Jiao et al., 
2014;Jiao et al., 
2015) 
lncRNA 
MALAT-1 
gastric cancer sequestering of miR-23b-3p; 
increased expression of 
ATG12; increased autophagy 
(YiRen et al., 
2017) 
lncRNA 
MIR100HG 
colon cancer increased activity of Wnt-ß-
catenin pathway 
(Lu et al., 2017b) 
lncRNA MRUL gastric cancer increasing the expression of 
MDR1 gene 
(Wang et al., 
2014) 
lncRNA 
PANDAR 
gastric cancer 
colorectal cancer 
hepatocellular 
cancer 
cholangiocarcinoma 
interacts with the 
transcription factor NF-YA 
resulting in reduced 
translation of pro-apoptotic 
genes – leading to reduced 
apoptosis rate and increased 
proliferation 
(Hung et al., 
2011;Peng and 
Fan, 2015;Ma et 
al., 2016a;Lu et 
al., 2017a;Xu et 
al., 2017b) 
lncRNA PVT1 gastric cancer 
oesophageal cancer 
pancreatic cancer 
colon cancer 
liver cancer 
 induced EMT (Zheng et al., 
2016;Wu et al., 
2017;Zhou et al., 
2017) 
lncRNA PVT-1 gastric cancer increasing the expression of 
MDR1 gene 
(Zhang et al., 
2015c;Lan et al., 
2016) 
lncRNA TUC338 hepatocellular 
cancer 
inhibiting the RASAL-1 
pathway 
(Jin et al., 2017) 
lncRNA TUG1 oesophageal cancer 
gastric cancer 
colorectal cancer 
hepatocellular 
cancer 
cholangiocarcinoma 
increasing the expression of 
Bc-2 gene; reducing the 
expression of cyclin-
dependent protein kinase, 
caspase-3, caspase-9 and 
Bax; decreasing G0/G1 arrest 
during cell cycle; reducing 
apoptosis rate; inducing EMT 
(Huang et al., 
2015;Dong et al., 
2016;Jiang et al., 
2016;Li et al., 
2016b;Wang et 
al., 2016a;Zhang 
et al., 2016a;Xu et 
al., 2017c) 
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lncRNA UCA1 
(identical with 
lncRNA CDUR) 
liver cancer  
colorectal cancer 
pancreatic cancer  
gastric cancer  
oesophageal cancer 
sequestering microRNAs 
(miR-216b in liver cancer; 
miR-204-5p in colorectal and 
oesophageal cancer; miR-27 
in gastric cancer); increase 
expression of lncRNAs 
(HULC; H19); increased 
activity of Wnt-ß-catenin 
pathway; increased activity of 
PI3K-AKT-mTOR pathway; 
increased phosphorylation of 
tumour suppressor 
retinoblastoma; increased 
expression of c-myc; 
increased cell-cycle 
progression; increased 
expression of anti-apoptotic 
protein Bcl-2; reduced 
expression of PARP (in 
gastric cancer); reduced 
apoptosis rate. In liver cancer 
additional effects: 
transformation of stem cells 
into cancer stem cells due to 
increased c-myc expression; 
increasing telomere length 
(Walker et al., 
1996;Hiyama and 
Hiyama, 
2007;Wang et al., 
2008;Gui et al., 
2015;Pu et al., 
2015;Bian et al., 
2016;Fang et al., 
2016a;Fang et al., 
2016b;Li and 
Chen, 2016;Shang 
et al., 2016;Chen 
et al., 2017;Li et 
al., 2017) 
lncRNA URHC liver cancer reduced expression of the 
tumour suppressor ZAK; 
increased proliferation rate; 
reduced apoptosis rate 
(Xu et al., 2014b) 
lncRNA-34a colon cancer increased activity of Wnt-ß-
catenin pathway; increased 
activity of NOTCH pathway; 
increasing the self-renewal of 
cancer stem cells 
(Bu et al., 
2013;Evans et al., 
2015) 
miR let-7 family pancreatic cancer induced EMT (Li et al., 2009) 
miR let-7a pancreatic tumours increased expression of 
RRM2 
(Bhutia et al., 
2013) 
miR let-7g oesophageal cancer increased expression of 
ABCC10 
(Wu et al., 2016a) 
miR let-7i oesophageal cancer increased expression of 
ABCC10 
(Wu et al., 2016a) 
miR-100 colon cancer increased activity of Wnt-ß-
catenin pathway 
(Lu et al., 2017b) 
miR-101 liver cancer increased expression of 
EZH2; increased activity of 
Wnt-ß-catenin pathway; 
increased expression of Mcl-
(Sasaki et al., 
2008;Xu et al., 
2014a;He et al., 
2016) 
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1; reduced apoptosis rate 
miR-10b colorectal cancer increased expression of anti-
apoptotic protein BIm 
(Nishida et al., 
2012) 
miR-103/107 gastric cancer reduced expression of 
tumour-suppressor caveolin-
1; activation of Ras-p42/p44 
MAP pathway; reduced 
apoptosis rate 
(Le Gall et al., 
2000;Mebratu and 
Tesfaigzi, 
2009;Zhang et al., 
2015d) 
miR-106a gastric cancer reduced expression of FAS; 
reduced apoptosis rate 
(Xiao et al., 
2009;Wang et al., 
2013c) 
miR-1182 gastric cancer increased expression of 
hTERT 
(Zhang et al., 
2015a) 
miR-122 liver cancer increased expression of ABC 
proteins; increased 
expression of cyclin G1; 
reduced G2/M cell-cycle 
arrest; reduced DNA repair; 
reduced apoptosis rate 
(Fornari et al., 
2009;Xu et al., 
2011) 
miR-124 pancreatic cancer 
 liver cancer 
reduced expression of 
SLC16A1 
(Pullen et al., 
2011) 
miR-125b colon cancer increased activity of Wnt-ß-
catenin pathway 
(Lu et al., 2017b) 
miR-1246 pancreatic cancer reduced expression of cyclin-
G2; de-regulated cell-cycle 
(Hasegawa et al., 
2014) 
miR-129 colorectal cancer increased expression of anti-
apoptotic protein Bcl-2 
(Karaayvaz et al., 
2013) 
miR-1291 pancreatic cancer increased expression of 
ABCC1 
(Pan et al., 2013) 
miR-130b liver cancer reduce expression of tumour 
protein 53-induced nuclear 
protein 1 
(Ma et al., 2010) 
miR-1307 pancreatic cancer reduced apoptosis rate  (Carotenuto et al., 
2018) 
miR-133a oesophageal cancer increased expression of 
GSTP1 
(Kano et al., 2010) 
miR-145 colon carcinoma increased expression of 
ABCB1 
(Ikemura et al., 
2013) 
miR-147 colon cancer induced EMT; increased 
phosphorylation of AKT; 
increased activity of PI3K-
AKT-mTOR pathway; 
increased activity of TGF-ß 
pathway 
(Lee et al., 2014) 
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miR-155 colorectal cancer inhibition of MSH2, MSH6 
and MLH1 
(Valeri et al., 
2010b) 
miR-15b gastric cancer increased expression of anti-
apoptotic protein Bcl-2 
(Xia et al., 2008) 
miR-16 gastric cancer increased expression of anti-
apoptotic protein Bcl-2 
(Xia et al., 2008) 
mir-17-5p colorectal cancer reduced expression of PTEN 
expression; activation of 
AKT-mTOR pathways 
(Fang et al., 2014) 
miR-17-5p pancreatic cancer reduced expression of BIM (Yan et al., 2012) 
miR-1915 colon cancer increased expression of BCL-
2 
(Xu et al., 2013) 
miR-192 colon cancer reduced expression of 
thymidylate synthase; altered 
cell-cycle control at multiple 
levels; prevent progression 
into the S-phase 
(Boni et al., 2010) 
miR-193b hepatocellular 
cancer 
increased expression of Mcl-
1 
(Braconi et al., 
2010) 
miR-195 colorectal cancer increased expression of anti-
apoptotic protein Bcl-2L2 
(Qu et al., 2015) 
miR-199a-3p liver cancer reduced G1/S cell-cycle 
arrest; increased expression 
of mTOR and c-Met; reduced 
apoptosis rate 
(Abukhdeir and 
Park, 
2008;Fornari et 
al., 2010) 
miR-19a gastric cancer reduced expression of PTEN 
expression; activation of 
AKT-mTOR pathways 
(Wang et al., 
2013a) 
miR-19b gastric cancer reduced expression of PTEN 
expression; activation of 
AKT-mTOR pathways 
(Wang et al., 
2013a) 
miR-200a pancreatic cancer induced EMT (Li et al., 2009) 
miR-200b pancreatic cancer induced EMT (Li et al., 2009) 
miR-200c pancreatic cancer induced EMT (Li et al., 2009;Yu 
et al., 2010) 
miR-203 colorectal cancer reduced expression of ATM; 
impaired DNA repair; 
reduced apoptosis rate 
(Zhou et al., 2014) 
miR-205 pancreatic cancer increased expression of 
pluripotent factors OKT3, 
OKT8 and CD44 
(Singh et al., 
2013) 
miR-21 colorectal cancer inhibition of MSH2 and 
MSH6; reduced G2/M cell-
cycle arrest; reduced 
apoptosis rate; increasing the 
number of undifferentiated 
cancer stem cells 
(Valeri et al., 
2010a;Yu et al., 
2013) 
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miR-21 pancreatic cancer reduced cell-cycle arrest; 
reduced expression of PTEN; 
activation of AKT-mTOR 
pathway; increased 
expression of anti-apoptotic 
protein Bcl-2; increased cell 
proliferation; reduced 
apoptosis rate 
(Giovannetti et al., 
2010;Dong et al., 
2011) 
miR-21 liver cancer  
gastric cancer 
reduced expression of PTEN 
expression; activation of 
AKT-mTOR pathways 
(Meng et al., 
2007;Zhang et al., 
2012;Yang et al., 
2013a) 
synergistic action 
of 
miR-21 
miR-23a 
miR-27a 
pancreatic cancer reduced expression of the 
tumour suppressors PDCD4, 
BTG2 and NEDD4L; de-
regulated cell-cycle; reduced 
apoptosis rate 
(Frampton et al., 
2014a;Frampton 
et al., 2014b) 
miR-211 pancreatic tumours increased expression of 
RRM2 
(Maftouh et al., 
2014) 
miR-215 liver cancer reduced expression of 
dihydrofolate reductase; 
reduced expression of 
thymidylate synthase 
(Wang et al., 
2015b) 
miR-215 colon cancer reduced expression of 
thymidylate synthase; altered 
cell-cycle control at multiple 
levels; prevent progression 
into the S-phase 
(Boni et al., 2010) 
miR-215 gastric cancer reduced expression of 
retinoblastoma 1; altered cell-
cycle control 
(Deng et al., 
2014;Xu and Fan, 
2015) 
miR-22 p53-mutated colon 
cancer 
reduced expression of PTEN 
expression; activation of 
AKT-mTOR pathways 
 
miR-221 oesophageal cancer reduced expression of DDK2; 
activation of Wnt/ß-catenin 
pathway; induced EMT 
(Li et al., 
2011;Wang et al., 
2016b) 
miR-223 liver cancer increased expression of 
ABCB1 
 
miR-223 pancreatic cancer induced EMT (Ma et al., 2015) 
miR-223 gastric cancer reduced expression of 
FBXW7; altered cell-cycle 
control 
(Zhou et al., 2015) 
miR-224 colon cancer induced EMT; increased 
phosphorylation of AKT und 
ERK; increased activity of 
PI3K-AKT-mTOR pathway; 
increased activity of ERK 
(Amankwatia et 
al., 2015) 
In r vi
w
Non-coding RNAs and anticancer drugs
 
 
pathway; activation of NF-
æB and EGFR dependent 
pathways 
miR-23a microsatellite 
instable colon 
cancer 
increased expression of 
ABCF1 
(Li et al., 2015c) 
miR-25 gastric cancer reduced expression of 
FOXO3a, ERBB2 and 
FBXW7; cell-cycle 
deregulation; reduced 
apoptosis rate 
(Zhao et al., 
2014a;Gong et al., 
2015;Li et al., 
2015a;He et al., 
2017) 
miR-26b liver cancer increased activation of NF-
æB 
(Fan et al., 
2008;Zhao et al., 
2014b) 
miR-27a liver cancer reduced expression of 
dihydropyrimidine 
dehydrogenase 
(Offer et al., 2014) 
miR-27b liver cancer increased expression of 
CYP1B1; reduced expression 
of dihydropyrimidine 
dehydrogenase 
(Offer et al., 
2014;An et al., 
2017) 
miR-27b pancreatic cancer reduced expression of 
CYP3A4– resulting in 
cyclophosphamide resistance 
due to missing drug 
activation 
(Pan et al., 2009) 
miR-297 colorectal cancer increased expression of 
ABCC2 
(Xu et al., 2012) 
miR-29a pancreatic cancer  
liver cancer 
reduced expression of 
SLC16A1 
(Pullen et al., 
2011) 
miR-29b pancreatic cancer  
liver cancer 
reduced expression of 
SLC16A1 
(Pullen et al., 
2011) 
miR-31 colorectal cancer cell-cycle deregulation; 
reduced apoptosis rate 
(Wang et al., 
2010b;Cekaite et 
al., 2012) 
miR-320 colon cancer increased expression of 
SOX4; inhibition of p53 
mediated apoptosis; reduced 
expression of FOXM1 and 
FOXQ1; cell-cycle 
deregulation 
(Wan et al., 
2015;Vishnubalaji 
et al., 2016) 
miR-338-3p p53 mutant 
colorectal cancer 
reduced expression of 
mTOR; increased autophagy 
and reduced apoptosis rate 
(Han et al., 2017) 
miR-34a colon cancer increased expression of anti-
apoptotic protein Bcl-2 
(Wang et al., 
2010a) 
miR-365 colon cancer increased expression of anti-
apoptotic protein Bcl-2 
(Nie et al., 2012) 
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miR-374b pancreatic cancer increased ATP7A expression (Schreiber et al., 
2016) 
miR-378 liver cancer increased expression of 
CYP2E1 
(Mohri et al., 
2010) 
miR-409-3p colon cancer increased expression of 
Beclin-1; increased 
autophagy pathway 
(Tan et al., 2016) 
miR-451 colon cancer increasing the self-renewal of 
cancer stem cells; increased 
expression of ABCB1 
(Bitarte et al., 
2011) 
miR-494 colon cancer reduced expression of 
dihydropyrimidine 
dehydrogenase 
(Chai et al., 2015) 
miR-503-5p colorectal cancer reduced expression of 
apoptotic protein PUMA 
(Xu et al., 2017a) 
miR-508-5p gastric cancer increased expression of 
ABCB1; increased 
expression of transcription 
factor ZNRD1 
(Shang et al., 
2014) 
miR-519d liver cancer reduced expression of G1-
checkpoint CDK inhibitor 
p21; reduced apoptosis rate 
(Fornari et al., 
2012) 
miR-522 colon cancer increased expression of 
ABCB5 
(Yang et al., 2015) 
miR-92b colon cancer reduced expression of 
SLC15A and SLC15A1 
(Dalmasso et al., 
2011) 
miR-939 gastric cancer increased expression of 
SLC34A2; activation of 
Ras/MEK/ERK pathway 
(Zhang et al., 
2017) 
miR-96 colorectal cancer reduced expression of anti-
apoptotic proteins XIAP and 
UBE2N 
(Kim et al., 2015) 
svRNAb all GI tumours reduced expression of 
CYP3A4 
(Persson et al., 
2009) 
vRNA hvg-1 all GI tumours transporting drugs away from 
the target and drug 
sequestration 
(Mossink et al., 
2003;Gopinath et 
al., 2010) 
vRNA hvg-2 all GI tumours transporting drugs away from 
the target and drug 
sequestration 
(Mossink et al., 
2003;Gopinath et 
al., 2010) 
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Table 2: Overview about the different categories of non-coding RNA molecules.  885 
 886 
Name Biological role 
circular RNA 
(circRNA) 
involved in forming RNA-protein complex that regulate gene 
transcription; involved in regulating gene expression at post-
transcriptional level by acting as miRNA sponge 
endogenous small 
interfering RNA 
(endo-siRNA) 
involved in repression of transposable elements, chromatin 
organisation as well as gene regulation at transcriptional and post-
transcriptional level 
extracellular RNA 
(exRNA) 
involved in intercellular communication and cell regulation 
long intergenic non-
coding RNA 
(lincRNA) 
involved in gene expression via directing chromatin-modification 
complexes to specific target regions; lincRNAs located in the 
cytoplasm function as scaffold to bring together proteins and other 
RNA categories (especially mRNAs and miRNAs)  
long non-coding 
RNA (lncRNA) 
involved in regulation of gene expression via binding to chromatin 
regulatory proteins; involved in regulating gene expression at post-
transcriptional level by acting as microRNA decoys; some lncRNAs 
are processed into microRNAs 
microRNA involved in fine tuning cell homeostasis by controlling gene 
expression at post-transcriptional level 
miRNA-offset-RNA 
(moRNA) 
unknown  
piwi-interacting 
RNA (piRNA) 
involved in maintain germline integrity by 
repressing transposable elements; involved in mRNA de-adenylation;  
ribosomal RNA 
(rRNA) 
component of the ribosomes; involved in protein synthesis  
small Cajal body 
RNA (scaRNA) 
component of the Cajal bodies; involved in the biogenesis of small 
nuclear ribonucleoproteins and by this influence splicing of pre-
mRNAs 
small interfering 
RNA (siRNA) 
involved in RNA interference pathway as part of anti-viral defence 
small nuclear RNA 
(snRNA) 
component of the spliceosome; involved in splicing of pre-mRNAs 
during post-transcriptional modifications 
small nucleolar 
RNA (snoRNA) 
component of the Cajal bodies; involved in modification and 
processing of snRNA, rRNA and tRNA precursors as well as in 
mRNA editing  
sno-derived RNA 
(sdRNA) 
component of the Cajal bodies; involved in alternative splicing of 
mRNAs; some sdRNAs control gene expression at post-
transcriptional level 
transcription 
initiation RNA 
(tiRNA) 
involved in regulation of RNA polymerase II dependent transcription 
transfer RNA 
(tRNA) 
involved in transporting amino acids to the ribosomes during 
translation 
vault RNA (vRNA) component of the vaults (large ribonucleoprotein complexes in 
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cytoplasm); unknown function 
 887 
 888 
Table 3: Approved targeted therapies for GI cancer  889 
Abbreviation used: HER2=human epidermal growth factor receptor 2 ; VEGFR=vascular 890 
endothelial growth factor receptor; PD-1=programmed cell death protein-1 ; RAF=rapidly 891 
accelerated fibrosarcoma; PDGFR=platelet-derived growth factor receptor; c-892 
KIT=SCFR=mast/stem cell growth factor receptor; EGFR=epidermal growth factor receptor; 893 
VEGF=vascular endothelial growth factor; RET=rearranged during transfection; MSI-894 
H=microsatellite instability-high 895 
GI cancer Drug Target 
Gastric cancer Trastuzumab HER2 
Ramucirumab VEGFR-2 
Pembrolizumab PD-1 
Hepatocellular cancer Sorafenib RAF, VEGFR-2, VEGFR-3, PDGFR, c-
KIT 
Colon cancer Cetuximab, 
Panitumumab 
EGFR 
Bevacizumab VEGF 
Regorafenib VEGFR-1, VEGFR-2, VEGFR-3, 
BRAF, c-KIT, RET, PDGFR 
Colon cancer with 
MSI-H  
Pembrolizumab PD-1 
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